Already in 2015, researchers found that P533KR, a P53 acetylation deficient mutant, lost the function of regulating cell cycle, aging and apoptosis, but retained its tumor inhibitory function and the ability to regulate the expression of metabolic targets. This evidence concerns the gene TP53 and neoplasm.